论文部分内容阅读
目的:探讨血清K19-2G2检测对肺癌的诊断价值及临床应用。方法:应用化学发光免疫分析方法检测150例肺癌患者(肺癌组)、50例肺部良性疾病患者(肺部良性疾病组)和150例健康体检者(对照组)血清K19-2G2浓度;同时检测血清CYFRA21-1浓度。结果:肺癌组血清K19-2G2浓度高于肺部良性疾病组(P<0.05)和对照组(P<0.01),K19-2G2检测肺癌的灵敏度为57.8%,特异性为99.0%,其灵敏度和特异性优于CYFRA21-1;在不同病理类型肺癌中,肺鳞癌组K19-2G2的水平明显高于其他各组,差异有统计学意义(P<0.05)。结论:K19-2G2是一种有效的非小细胞肺癌肿瘤标志物,尤其适用于肺鳞癌的诊断。
Objective: To investigate the diagnostic value of serum K19-2G2 in lung cancer and its clinical application. Methods: The chemiluminescent immunoassay was used to detect the serum concentration of K19-2G2 in 150 patients with lung cancer (lung cancer group), 50 patients with benign lung disease (benign pulmonary disease group) and 150 healthy controls (control group) Serum CYFRA21-1 concentration. Results: The serum concentration of K19-2G2 in lung cancer group was higher than that in benign lung disease group (P <0.05) and control group (P <0.01). The sensitivity and specificity of K19-2G2 in detecting lung cancer were 57.8% and 99.0% Specificity was better than that of CYFRA21-1; in different pathological types of lung cancer, the level of K19-2G2 in lung squamous cell carcinoma was significantly higher than that in other groups (P <0.05). Conclusion: K19-2G2 is an effective non-small cell lung cancer tumor marker, especially for the diagnosis of squamous cell lung cancer.